Adjuvants MPLA and SMNP induce antiviral immunity and indirectly revert HIV-1 latency
Jade Jansen, Killian E. Vlaming, Leanne C. Helgers, Eva Schumacher, Tanja M. Kaptein, Rogier W. Sanders, Godelieve J. de Bree, Teunis B. H. Geijtenbeek, Neeltje A. Kootstra
This study shows that SMNP, a TLR4-targeted adjuvant, induces stronger immune activation and reduces HIV-1 reservoir size in PWH ex vivo compared to MPLA.
PLoS ONE · Jul 20, 2026Peer-reviewedImmunology